Long term antipsychotic treatment shows diminishing benefits, weak evidence for first episode psychosis, and substantial confounding from withdrawal effects. Psychosocial interventions—particularly Cognitive Behavioral Therapy and Open Dialogue—demonstrate superior functional and recovery outcomes. Current evidence supports shifting from lifelong antipsychotic maintenance toward recovery oriented, medication free or reduced medication approaches. Calling all medication-free treatment ideological is not supported by current evidence

Contence

1.Reassessing Long-Term Antipsychotic Use, Systemic Failures, and the Evidence for Psychosocial Interventions 1

Introduction: An Engineer's Perspective on Psychiatry 1

Science: Weak evidence for first episode psychosis, and substantial confounding from withdrawal effects 2

Science: Psychosocial interventions—particularly Cognitive Behavioral Therapy and Open Dialogue—demonstrate superior functional and recovery outcomes 4

The Reality of the Norwegian System: Policy vs. Practice 5

The Legal Turning Point: Landmark Rulings on Human Rights 6

Deconstructing the Paternalistic Dogma: A Response to Stefan Leucht 6

The Scientific Contradiction: Leucht's Own Data vs. His Rhetoric 7

The True Cost of Tolerability 7

Conclusion: A Imperative for a Recovery-Oriented Paradigm 8

Introduction: An Engineer's Perspective on Psychiatry

As a graduate in physical engineering, my entire professional life has been anchored in data, systemic analysis, and the rigorous verification of evidence. In engineering, when a system consistently fails or produces severe, unintended side effects, we do not simply double down on the faulty mechanism. We analyze the root cause, re-examine the foundational assumptions, and pivot toward solutions that are empirically proven to work. Unfortunately, when I turned my analytical lens toward modern psychiatry—specifically the treatment of schizophrenia and the widespread reliance on long-term antipsychotic maintenance—I discovered a profound disconnect between clinical dogma and empirical reality.

My journey into this field was not born out of abstract academic curiosity. It was forged through extensive personal exposure to the mental health system in Norway, where I documented severe, systematic violations of patient autonomy and a pervasive reliance on forced medication. These experiences forced me to confront a troubling truth: the very institutions tasked with healing individuals are frequently causing profound, long-lasting harm under the guise of medical necessity. This realization led me to thoroughly investigate the scientific literature, legal frameworks, and international human rights standards surrounding psychiatric care.

Science: Weak evidence for first episode psychosis, and substantial confounding from withdrawal effects

International concern is growing regarding the dominance of the biomedical model in mental health care. The United Nations Special Rapporteur on the right to health has argued that global mental health systems rely excessively on psychotropic medication and insufficiently on psychosocial interventions¹. This critique aligns with emerging evidence questioning the long term effectiveness of antipsychotics and highlighting the benefits of psychosocial approaches²,³.

Antipsychotics reduce relapse rates from 65% to 27% within one year⁴. However, this benefit is strongly time dependent, with meta analytic evidence showing substantial decline after two years⁵,⁶. Long term functional outcomes may even favor discontinuation: a four year randomized controlled trial reported better functioning three years after discontinuation compared to maintenance therapy⁷.

No placebo controlled trials include antipsychotic naïve participants, limiting the validity of conclusions about efficacy in first episode psychosis. The Norwegian Institute of Public Health concuded: "It is uncertain if antipsychotics compared to placebo affects symptoms in persons with early psychosis"⁹. Systematic reviews highlight that withdrawal effects in placebo groups compromise the interpretability of existing trials¹⁰. Despite this, antipsychotic prescribing remains nearly universal in some countries, with rates exceeding 97% in first episode psychosis¹⁵.

Across sixty years of placebo controlled trials, only 9% of patients achieve a “good response” attributable to antipsychotics¹². The majority do not experience clinically meaningful improvement, raising questions about the centrality of antipsychotics in acute care.

Systematic reviews find no robust evidence supporting long term antipsychotic therapy¹³. The CATIE trial, involving 1,124 participants, reported a 72% discontinuation rate, underscoring tolerability and effectiveness challenges²⁰. These findings suggest that long term pharmacotherapy may not align with patient experience or long term recovery trajectories. The studies of Harrow and Wunderink support tis argument.

Science: Psychosocial interventions—particularly Cognitive Behavioral Therapy and Open Dialogue—demonstrate superior functional and recovery outcomes

Psychosocial interventions—including Cognitive Behavioral Therapy, supportive psychotherapy, and Open Dialogue—demonstrate superior outcomes in symptoms, functioning, and quality of life²,see WHO 2023 (mhGAP) guideline³, and Ranjan, R. et al. 2025¹⁴. Long term observational data from Open Dialogue show substantially lower medication use, reduced disability, and fewer readmissions¹¹,¹⁵. Despite strong evidence, these interventions remain underutilized due to systemic and cultural barriers¹⁶,¹⁷.

Open Dialogue versus treatment as usual (TAU) for adults presenting in crisis to mental health services in England (the ODDESSI Trial) is a multisite cluster-randomised 2 years trial. Although Open dialogue uses less medication the time to first relapse was not inferior compared to TAU. Open Dialogue reduced acute inpatient bed use, improved service user reported outcomes and experience, and there were no significant safety concerns.

Some authors describe medication free approaches as ideological²¹. However, this framing assumes that antipsychotics are both effective and tolerable long term—conditions not supported by current evidence. A rational, evidence based approach requires reconsidering the default of lifelong medication and expanding access to psychosocial interventions.

The cumulative evidence challenges the assumption that lifelong antipsychotic treatment is necessary or beneficial for most individuals with schizophrenia. Psychosocial interventions demonstrate superior long term outcomes and align with patient preferences¹⁸,¹⁹. A recovery oriented paradigm emphasizing medication free or reduced medication approaches is warranted and consistent with international calls for reform¹. A shift of paradigm may promote recovery²².

The Reality of the Norwegian System: Policy vs. Practice

Norway is often lauded internationally for its progressive mental health policies. In 2016, the Norwegian Ministry of Health issued a historic directive mandating that all regional health authorities establish medication-free treatment units. This was a monumental victory for patient organizations who had campaigned for decades for the right to choose treatment paths that do not involve heavy neuroleptics. The policy was designed to give patients a voice, offering structured psychosocial support, physical exercise, and tailored therapies instead of immediate, forced chemical intervention.

However, there is a vast and devastating chasm between official policy and ground-level practice. In reality, the implementation of medication-free options has been fiercely resisted by the psychiatric establishment, and the actual availability of these beds remains microscopic. More alarmingly, the practice of forced drugging remains exceptionally high in Norway compared to other European nations. My own extensive documentation of these practices—shared publicly to expose these failures—reveals that the supervisory authorities, specifically the State Governor (Statsforvalteren) and the Directorate of Health (Helsedirektoratet), routinely rubber-stamp decisions for forced medication.

When patients appeal against forced treatment, their complaints are almost systematically dismissed. The legal protections intended to safeguard vulnerable citizens have mutated into bureaucratic exercises that shield the psychiatric system from accountability. This lack of reall-world self-determination is not just a clinical failure; it is a profound failure of governance and human rights oversight.

The Legal Turning Point: Landmark Rulings on Human Rights

For years, activists and affected individuals argued that these practices violated fundamental human rights, only to be met with institutional denial. However, the legal landscape in Norway has recently undergone a seismic shift. Landmark judicial decisions have shattered the illusion of legal compliance within the psychiatric sector, providing irrefutable proof of systemic human rights violations.

The first major breakthrough was the Eidsvik case (Borgarting Court of Appeal, January 2026). Inger-Mari Eidsvik, supported by the pro bono group of ICJ-Norway, successfully sued the state. The court ruled that the state had violated the European Convention on Human Rights (ECHR), specifically Article 3 (prohibition of inhuman or degrading treatment) and Article 8 (right to respect for private and family life). The court made it clear that informal procedures, lack of proper documentation, and arbitrary forced medication constitute a direct assault on a person's physical and psychological integrity. Crucially, the judgment established that the state cannot escape its human rights obligations by delegating authority to local health trusts.

Shortly thereafter, another harrowing case came to light: the Helen Wesnes case (Romerike and Glåmdal District Court, June 2026). Helen Wesnes was subjected to a staggering 15 years of erroneous psychiatric treatment, during which she was forcibly medicated, locked in isolation, and placed in mechanical restraints a shocking 78 times. It was later revealed that her initial diagnosis of schizophrenia was entirely incorrect. The district court delivered a scathing judgment against the state, awarding Wesnes 4.5 million NOK in damages for gross violations of ECHR Articles 3, 5 (right to liberty and security), and 8. These cases are not isolated incidents; they are symptomatic of an unaccountable system that routinely overrides human rights in the name of paternalistic medicine.

Deconstructing the Paternalistic Dogma: A Response to Stefan Leucht

Despite these damning legal defeats and a growing global consensus demanding reform, prominent figures within the psychiatric establishment continue to defend the status quo with aggressive rhetoric. A prime example of this defensive posture can be found in a recent article published in Nature (2025) by Dr. Stefan Leucht, a highly influential psychiatrist known for his extensive work on antipsychotic trials. In his advice to clinicians, Dr. Leucht writes:

'There is a "medication-free life" ideology that extends beyond psychiatry. It is an ideology because, if medication helps a patient remain well and is tolerable, it is irrational to stop it. We need to empower both clinicians and patients to make rational decisions.'

As an engineer trained to evaluate hypotheses based strictly on objective data, I find Dr. Leucht’s assertion deeply troubling, scientifically flawed, and actively misleading. To label the desire for a medication-free life as an 'ideology' or to dismiss the discontinuation of neuroleptics as 'irrational' is a form of gaslighting that ignores both patient preference and massive bodies of empirical data. Ironically, Dr. Leucht’s own collaborative research directly contradicts the very paternalistic message he is now promoting.

The Scientific Contradiction: Leucht's Own Data vs. His Rhetoric

Let us examine the actual scientific evidence. Dr. Leucht was a co-author of the World Health Organization’s (WHO) 2023 mhGAP guidelines. The conclusions were explicit and unambiguous: Cognitive Behavioral Therapy (CBT) was significantly superior to treatment as usual (TAU) across multiple critical outcomes, including 'overall symptoms', 'quality of life', and 'functioning'.

The WHO 2023 guidelines themselves heavily emphasize the utilization of psychosocial interventions, including CBT and family therapies, as essential components of recovery. If the highest level of psychiatric evidence demonstrates that non-pharmacological, psychosocial interventions result in superior long-term functioning and quality of life, how can seeking a life free from heavy chemical dependency be branded as an 'irrational ideology'?

Furthermore, the assumption that long-term antipsychotic maintenance is universally beneficial is built on remarkably weak foundations. A critical analysis of first-episode psychosis literature reveals a shocking lack of long-term, placebo-controlled trials involving antipsychotic-naïve participants. Most maintenance studies suffer from a severe confounding variable: drug withdrawal effects. When a patient abruptly stops a powerful neuroleptic, the brain—which has adapted to severe dopamine blockade—experiences a state of dopaminergic supersensitivity. This frequently triggers a severe relapse. Culturally, psychiatry interprets this relapse as proof of the underlying illness, whereas an objective system analysis reveals it is often an artifact of drug withdrawal. Long-term outcome studies, such as the landmark longitudinal research by Martin Harrow and colleagues, have repeatedly shown that individuals with schizophrenia who discontinue antipsychotics exhibit significantly higher recovery rates and better global functioning over a 20-year period compared to those who remain continuously medicated. Lex Wunderins well-known study confirms this in a 7-year study.

The True Cost of Tolerability

Dr. Leucht’s argument hinges entirely on the phrase 'if medication helps a patient remain well and is tolerable.' This completely minimizes the profound, documented toxicities of long-term neuroleptic use. Antipsychotic medications are associated with structural brain changes, severe metabolic syndrome, cardiovascular disease, tardive dyskinesia, and a dramatically shortened life expectancy—often reduced by 15 to 20 years. For a patient to decide that these physical risks outweigh the marginal, short-term benefits of symptom suppression is not 'irrational.' It is a highly rational, calculated decision about their own bodily integrity and long-term survival.

When we look at alternative care paradigms like the Open Dialogue approach developed in Western Lapland, Finland, we see the practical proof of a reduced-medication framework. Open Dialogue prioritizes immediate psychosocial and network-based intervention, utilizing antipsychotic medications conservatively and only if absolutely necessary. The long-term results are astonishing: approximately 80% of patients return to full-time employment or study, and the vast majority remain completely free of antipsychotic medications at long-term follow-up. This is not an 'ideology'; it is an empirically verified, highly successful clinical reality.

Conclusion: A Imperative for a Recovery-Oriented Paradigm

The evidence is clear, whether it comes from the World Health Organization’s (WHO) 2023 mhGAP guidelines, the harrowing legal judgments of the Norwegian courts, or the lived experiences of thousands of individuals who have suffered under forced treatment. The current psychiatric paradigm, which prioritizes lifelong chemical maintenance and treats patient resistance as irrational, is unsustainable and harmful.

We must align clinical practice with contemporary evidence and human rights standards, as demanded by the United Nations Special Rapporteur on the right to health. This means dismantling the bureaucratic structures—such as those overseen by the Norwegian Helsedirektoratet—that permit rampant, unconstitutional forced drugging. It means investing heavily in genuine medication-free alternatives, CBT, and systemic approaches like Open Dialogue.

True empowerment does not mean convincing a patient to 'rationally' accept lifelong chemical restraint. True empowerment means respecting their autonomy, defending their legal rights, and providing them with the psychosocial tools necessary to achieve a self-determined recovery. A medication-free life is not a dangerous ideology; it is a fundamental human right.

1.Reassessing Long-Term Antipsychotic Use, Systemic Failures, and the Evidence for Psychosocial Interventions

Abstract